Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Puma Biotechnology (PBYI) FCF Margin (2017 - 2025)

Historic FCF Margin for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to 17.76%.

  • Puma Biotechnology's FCF Margin rose 40800.0% to 17.76% in Q3 2025 from the same period last year, while for Sep 2025 it was 20.23%, marking a year-over-year increase of 64000.0%. This contributed to the annual value of 16.86% for FY2024, which is 54600.0% up from last year.
  • Per Puma Biotechnology's latest filing, its FCF Margin stood at 17.76% for Q3 2025, which was up 40800.0% from 26.83% recorded in Q2 2025.
  • Puma Biotechnology's 5-year FCF Margin high stood at 26.83% for Q2 2025, and its period low was 58.8% during Q1 2022.
  • Moreover, its 5-year median value for FCF Margin was 14.42% (2023), whereas its average is 7.68%.
  • In the last 5 years, Puma Biotechnology's FCF Margin tumbled by -747600bps in 2022 and then skyrocketed by 638100bps in 2023.
  • Quarter analysis of 5 years shows Puma Biotechnology's FCF Margin stood at 9.82% in 2021, then skyrocketed by 271bps to 16.75% in 2022, then decreased by -14bps to 14.42% in 2023, then skyrocketed by 83bps to 26.39% in 2024, then plummeted by -33bps to 17.76% in 2025.
  • Its FCF Margin was 17.76% in Q3 2025, compared to 26.83% in Q2 2025 and 7.72% in Q1 2025.